0031 GMT - Sonic Healthcare gets a sell call from Citi, which says Australian Medicare data for pathology looks worse than it expected. "Sonic's results are not perfectly correlated but we have halved our near-term growth forecasts for Australia revenue [circa 20% of the top line] to 2.5%," says analyst Laura Sutcliffe. Citi also thinks Sonic's U.S. business could continue to underperform. It points to mid-single digit growth estimates from larger competitors which have recently outperformed Sonic. "Our 1H revenue estimates are near consensus, but we are 5% below for net profit," Citi says. "We put in place a negative 30-day catalyst watch." It downgrades Sonic to sell, from neutral, and lowers its price target by 11% to A$21.00. Sonic is down 2.9% at A$22.66. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

January 26, 2026 19:31 ET (00:31 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.